EP, US, JP, CA pending
Leucotox starts compound modification for increased treatment efficacy
EPO Patent Publication
LeucoTox performed first patient-derived xenograft experiments with substantial treatment efficacy.
Preclinical models show efficacy of LeucoTox in myeloid leukemia in vivo.
LeucoTox submitted patent application at the European Patent Office.